ReviewTherapeutic advances in hematology2016
Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience.
Review in Therapeutic advances in hematology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 31 citations in OpenAlex.
- Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenström macroglobulinemia.Haematologica · 2018Trial
- Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results.British journal of haematology · 2018Trial
- Potential Off-Target Effect of Gilteritinib With Venetoclax Decreases Tumor Burden for Patients With Relapsed/Refractory Wild-TypeCase reports in hematology · 2025Article
- Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
- Clinical, biological, electrophysiological and therapeutic profile of patients with anti-MAG neuropathy according to MYD88Journal of neurology · 2024Article
- Ibrutinib impairs IGF-1-dependent activation of intracellular Ca handling in isolated mouse ventricular myocytes.Frontiers in cardiovascular medicine · 2023Article
- TLR-mediated activation of Waldenström macroglobulinemia B cells reveals an uncoupling from plasma cell differentiation.Blood advances · 2020Article
- The role of histone lysine demethylases in cancer cells' resistance to tyrosine kinase inhibitors.Cancer drug resistance (Alhambra, Calif.) · 2019Review
- Response to Ibrutinib of a Refractory IgA Lymphoplasmacytic Lymphoma Carrying theMediterranean journal of hematology and infectious diseases · 2019Article
- Review
- Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia.Haematologica · 2018Article
- A Specific and Covalent JNK-1 Ligand Selected from an Encoded Self-Assembling Chemical Library.Chemistry (Weinheim an der Bergstrasse, Germany) · 2017Article
- Ibrutinib-Associated Skin Toxicity: A Case of Maculopapular Rash in a 79-Year Old Caucasian Male Patient with Relapsed Waldenstrom's Macroglobulinemia and Review of the Literature.Dermatology reports · 2017Article
- Cost-effectiveness analysis of ibrutinib in patients with Waldenström macroglobulinemia in Italy.Journal of market access & health policy · 2017Article
- Severe Hepatotoxicity due to Ibrutinib with a Review of Published Cases.Case reports in gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
Abstract
Ibrutinib is an oral Bruton's tyrosine kinase (BTK) inhibitor, which has recently gained approval by the United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of patients with symptomatic Waldenström macroglobulinemia (WM). Herein, we review the role of BTK in the pathophysiology of WM, and present the results of the preclinical and clinical studies that led to the initial investigation and later approval of ibrutinib in WM. We also discuss aspects associated with ibrutinib therapy in WM patients, especially focusing on genomic profiling and the impact on response to ibrutinib, and the management of adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.